Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Children With Active Juvenile Psoriatic Arthritis (PEAPOD)
NCT04804553Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Mar 2022
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in juvenile psoriatic arthritis (JPsA) comparing Apremilast with Placebo to Apremilast (2 arms). Primary endpoint: American College of Rheumatology Pediatric 30 Response at 16 weeks. Started Mar 2022; status: recruiting.
02
Drugs
apremilast
03
Conditions
juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on NCT04804553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04804553.